Tired of using multiple mice for your immunoassay studies?

Reducing the number of mice used in biomarker studies has advantages ranging from cost savings to supporting reduction in the use of animals for research. In particular, biomarker time course studies in mice have inherently used many animals due to the large sample volumes needed for immunoassays necessitating one mouse per one time point. Most Luminex® xMAP® immunoassays require 25 ul of sample to run assays. Curiox’s DA technology miniaturizes the Luminex assay by reducing, in proportionate amounts to obtain equivalent results, the reagents and samples needed for the assays. With DA, sample volumes as low as 2ul can be achieved and this is well below the volume that can be withdrawn from the same mouse to run short interval studies.

Luminex® xMAP® Immunoassay Resources

Luminex xMAP technology is widely used for multiplex immunoassays. However, their business model is very confusing to customers in terms of who sells instruments and/or assays. Also, it’s difficult to get information that’s accurate because one partner may tell you something, and then Luminex, or another partner, may tell you something completely contradictory. In order to help you navigate this complex partner business model, we have compiled a list of resources for you that can help you navigate this complex web of the technology inventor (Luminex Corp.) and their distributors/partners for research immunoassays.

How to Minimize Matrix Effects for Luminex® xMAP® Assays

Multiplexed bead assays have always been prone to aggregation, especially in the presence of complex biological fluids and matrices. The inherent properties of magnetic beads in regards to size, magnetism, and coatings (both polymer and conjugated protein) can lead the magnetic particles to clump or aggregate during the assay incubations, washings, and resuspensions.

Who made the rules about how many beads in multiplex assays?

Curiox Biosystems is proud to announce the rapid adoption of the DropArray system to miniaturize multiplexing immunoassays. Three major companies, Charles River Labs, and major biopharmaceutical companies on the east and west coast of the U.S., have adopted the technology as an enhancement to their bead-based multiplexing systems.

Curiox Biosystems Announces New Distributors in Europe

Curiox Biosystems is proud to announce the addition of three new distributors in Europe for the DropArray™ System. The three distributors include Cambridge Bioscience covering the United Kingdom, CliniSciences servicing France and THP Biomedical supplying Austria, Czech Republic, Slovakia, Hungary, and Slovenia.

Curiox Biosystems Webinar: Luminex® Cytokine Assay on Wall Less Plates: Direct Comparison to Conventional Plate Assay in an Ascaris suum Immunogenicity Study

Curiox Biosystems Webinar: Luminex® Cytokine Assay on Wall Less Plates: Direct Comparison to Conventional Plate Assay in an Ascaris suum Immunogenicity Study.

This webinar will be presented by Dr. Coreen Beaumier, current Co-Director of Product Development for the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development in Houston, TX.

She directs the product development of tropical disease vaccines and manages the projects and programs for these endeavors from antigen discovery to product related matters during clinical trials. In addition to her Co-Director role, she holds the position of Assistant Professor at Baylor College of Medicine in the Tropical Medicine Section of the Pediatrics Department, part of the National School of Tropical Medicine. As Assistant Professor, Dr. Beaumier leads the Immunology Unit of laboratories, teaching immunological courses within Baylor College of Medicine, and mentoring students and fellows in their research.

Curiox Biosystems Welcomes Seasoned Life Science Professionals Robert Bunzel and Charles Martin

Curiox Biosystems is proud to welcome two highly experienced life science professionals to the team, Robert Bunzel and Charles Martin.

Robert (Bob) comes to us from Meso Scale Discovery where he covered the Southeastern U.S. Prior to that, he was the business manager for two multiplexing strongholds, Luminex and Millipore. Bob’s brings a track record of success in the multiplex instrumentation and reagent arena. Bob will be covering the Midwest and South for Curiox. Please contact Bob at rbunzel@curiox.com.

Charles Martin joins Curiox from SomaLogic where he was the Director of Marketing for Life Sciences. Prior to that, Charles led a team of field marketers and applications scientists for Luminex Corporation. He also held various marketing positions at Bio-Rad. Charles will be covering the Western U.S. Please contact Charles at charlesm@curiox.com.

WEBINAR: Miniaturization of Luminex Cytokine Multiplexing Assay to Detect Early Cytokine Changes in a Mouse Model

Subhabrata Biswas, Ph.D., MBA, of Merck Research Laboratory in Boston, MA. Dr. Biswas will discuss his mouse model and detail his comparative analysis of conventional Luminex assays vs. the addition of the Curiox DropArray™ System to enhance his results. The relevance of using the DropArray system in lieu of the conventional method with regards to assay sensitivity, analyte detectability and decreasing assay costs with minimal changes to the standard workflow will be discussed.

Human tear analysis with miniaturized multiplex cytokine assay on “wall-less” 96-well plate

Tears are a particularly limited body fluid and commonly used in the diagnosis of patients who have ocular diseases. A popular method for analysis of ocular inflammation in tears uses Luminex® bead multiplex technology to generate valuable multiple cytokine profile outputs with 25–50 µl tear sample volume. We propose a method for measuring tear cytokines with 5 μl tear sample volume and 80% reduced Luminex reagents compared to previous protocols.